Chimerix, Inc.
2505 Meridian Parkway
Durham
North Carolina
27713
United States
Website: http://www.chimerix-inc.com/
325 articles about Chimerix, Inc.
-
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
2/29/2024
Chimerix reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.
-
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
2/27/2024
Chimerix announced that Mike Andriole, Chief Executive Officer, will participate in a Targeted Oncology Panel at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:50 p.m. ET.
-
Chimerix Appoints Lisa Decker to Board of DirectorsSeasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience
12/29/2023
Chimerix announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors.
-
Chimerix Promotes Michelle LaSpaluto to Chief Financial OfficerProven Leader Brings More Than 25 Years of Financial Experience
12/4/2023
Chimerix today announced the promotion of Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective December 1, 2023.
-
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/24/2023
Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock.
-
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
11/16/2023
Chimerix, a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced the appointment of Thomas Riga as Chief Operating and Commercial Officer.
-
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
11/2/2023
Chimerix reported financial results for the third quarter ended September 30, 2023 and provided an operational update.
-
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
10/26/2023
Chimerix announced that it will host a live conference call and audio webcast on Thursday, November 2, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business overview.
-
Chimerix to Participate in Upcoming September 2023 Investor Conferences
9/5/2023
Chimerix, a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced that management will participate in two upcoming investor conferences.
-
Boehringer Ingelheim will launch three Phase III studies for its obesity drug candidate; third time is a charm for Ipsen as it gets FDA approval; and Pfizer takes multiple myeloma battle to J&J.
-
The company’s first-in-class small molecule imipridone, ONC201, showed strong efficacy results in two early-stage clinical trials of 71 pediatric patients with H3K27M-mutant diffuse midline gliomas.
-
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
8/16/2023
Chimerix (NASDAQ:CMRX) today announced the publication of data in support of the Company’s first-in-class small molecule imipridone, ONC201, as a treatment for H3 K27M-mutant diffuse midline gliomas (H3K27M-DMG) in the peer-reviewed journal, Cancer Discovery, a journal of the American Association for Cancer Research.
-
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
8/3/2023
Chimerix, a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, reported financial results for the second quarter ended June 30, 2023 and provided an operational update.
-
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
7/27/2023
Chimerix today announced that it will host a live conference call and audio webcast on Thursday, August 3, 2023 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2023, and to provide a business overview.
-
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
6/27/2023
Chimerix, Inc. announced the promotion of Mike Andriole, Chief Business Officer and Chief Financial Officer, to President and Chief Executive Officer of Chimerix and his appointment to the Board of Directors.
-
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
5/31/2023
Chimerix (NASDAQ:CMRX) today announced that Mike Sherman, Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 3:30 p.m. in New York City.
-
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update
5/4/2023
Chimerix today reported financial results for the first quarter ended March 31, 2023 and provided an operational update.
-
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023
4/27/2023
Chimerix (NASDAQ:CMRX) today announced that it will host a live conference call and audio webcast on Thursday, May 4, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023, and to provide a business overview.
-
Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting
4/18/2023
Chimerix announced a summary of presentations at the American Association for Cancer Research Annual Meeting, taking place April 14-19, 2023 in Orlando, FL.
-
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update
3/2/2023
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided an operational update.